Literature DB >> 19259130

Segregation analysis in a family at risk for the Maroteaux-Lamy syndrome conclusively reveals c.1151G>A (p.S384N) as to be a polymorphism.

Alessandra Zanetti1, Elena Ferraresi, Luigi Picci, Mirella Filocamo, Rossella Parini, Camillo Rosano, Rosella Tomanin, Maurizio Scarpa.   

Abstract

Maroteaux-Lamy syndrome is an autosomal-recessive disorder due to the deficit of the lysosomal enzyme, arylsulfatase B (ARSB). Among the numerous genomic lesions reported till now, the sequence variant, c.1151G>A (p.S384N), has been associated with a severe phenotype in more than 10% of the patients. We now report the first in vivo demonstration of the polymorphic nature of p.S384N, revealed during the segregation analysis in a family at risk for Maroteaux-Lamy syndrome. The proband, compound heterozygous for c.[944G>A]+[245T>G] (p.[R315Q]+[L82R]), did not carry the p.S384N change, which was instead present in two healthy members of the family, in trans with the causative mutations, p.R315Q and p.L82R, respectively. The hypothesis that p.S384N was a polymorphism was further addressed by reverse dot-blot analysis of 400 control alleles, estimating an allele frequency of 4.5%. To predict the consequences of p.R315Q, p.L82R and p.S384N, we also modeled and compared the three amino-acid changes in the three-dimensional ARSB structure. The in silico analysis predicted a local protein misfolding in the presence of p.R315Q and p.L82R. On the contrary, no evident problem was predicted in the case of p.S384N, occurring on the protein surface, far from the active site. Overall, these findings strongly support the hypothesis that the non-synonymous change p.S384N is a polymorphism. Moreover, our results emphasize the need for caution in drawing conclusions from a novel variant allele before screening at least 50 healthy control subjects.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19259130      PMCID: PMC2986599          DOI: 10.1038/ejhg.2009.19

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  17 in total

1.  Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion.

Authors:  J T den Dunnen; S E Antonarakis
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

2.  Standardizing mutation nomenclature: why bother?

Authors:  Johan T den Dunnen; Mark H Paalman
Journal:  Hum Mutat       Date:  2003-09       Impact factor: 4.878

3.  The assay of arylsulphatases A and B in human urine.

Authors:  H BAUM; K S DODGSON; B SPENCER
Journal:  Clin Chim Acta       Date:  1959-05       Impact factor: 3.786

4.  UCSF Chimera--a visualization system for exploratory research and analysis.

Authors:  Eric F Pettersen; Thomas D Goddard; Conrad C Huang; Gregory S Couch; Daniel M Greenblatt; Elaine C Meng; Thomas E Ferrin
Journal:  J Comput Chem       Date:  2004-10       Impact factor: 3.376

5.  Improved methods for building protein models in electron density maps and the location of errors in these models.

Authors:  T A Jones; J Y Zou; S W Cowan; M Kjeldgaard
Journal:  Acta Crystallogr A       Date:  1991-03-01       Impact factor: 2.290

Review 6.  Mucopolysaccharidosis type VI: Structural and clinical implications of mutations in N-acetylgalactosamine-4-sulfatase.

Authors:  T Litjens; J J Hopwood
Journal:  Hum Mutat       Date:  2001-10       Impact factor: 4.878

7.  Structure of a human lysosomal sulfatase.

Authors:  C S Bond; P R Clements; S J Ashby; C A Collyer; S J Harrop; J J Hopwood; J M Guss
Journal:  Structure       Date:  1997-02-15       Impact factor: 5.006

8.  Detection of multiple cystic fibrosis mutations by reverse dot blot hybridization: a technology for carrier screening.

Authors:  F F Chehab; J Wall
Journal:  Hum Genet       Date:  1992-05       Impact factor: 4.132

9.  An index case for the attenuated end of the mucopolysaccharidosis type VI clinical spectrum.

Authors:  Doug A Brooks; Gary J Gibson; Litsa Karageorgos; Leanne K Hein; Evelyn F Robertson; John J Hopwood
Journal:  Mol Genet Metab       Date:  2005-03-24       Impact factor: 4.797

10.  Maroteaux-lamy syndrome: five novel mutations and their structural localization.

Authors:  G R Villani; N Balzano; D Vitale; M Saviano; V Pavone; P Di Natale
Journal:  Biochim Biophys Acta       Date:  1999-02-24
View more
  8 in total

Review 1.  Mucopolysaccharidosis VI.

Authors:  Vassili Valayannopoulos; Helen Nicely; Paul Harmatz; Sean Turbeville
Journal:  Orphanet J Rare Dis       Date:  2010-04-12       Impact factor: 4.123

2.  Molecular testing of 163 patients with Morquio A (Mucopolysaccharidosis IVA) identifies 39 novel GALNS mutations.

Authors:  A Morrone; K L Tylee; M Al-Sayed; A C Brusius-Facchin; A Caciotti; H J Church; M J Coll; K Davidson; M J Fietz; L Gort; M Hegde; F Kubaski; L Lacerda; F Laranjeira; S Leistner-Segal; S Mooney; S Pajares; L Pollard; I Ribeiro; R Y Wang; N Miller
Journal:  Mol Genet Metab       Date:  2014-03-20       Impact factor: 4.797

3.  Molecular Analysis of Turkish Maroteaux-Lamy Patients and Identification of One Novel Mutation in the Arylsulfatase B (ARSB) Gene.

Authors:  Alessandra Zanetti; Neslihan Onenli-Mungan; Nursel Elcioglu; Mehmet Nuri Ozbek; Deniz Kör; Elisabetta Lenzini; Maurizio Scarpa; Rosella Tomanin
Journal:  JIMD Rep       Date:  2013-11-16

Review 4.  Lysosomal storage disorders: molecular basis and laboratory testing.

Authors:  Mirella Filocamo; Amelia Morrone
Journal:  Hum Genomics       Date:  2011-03       Impact factor: 4.639

Review 5.  Morquio A syndrome-associated mutations: a review of alterations in the GALNS gene and a new locus-specific database.

Authors:  Amelia Morrone; Anna Caciotti; Robert Atwood; Kathryn Davidson; Chaoyi Du; Patricia Francis-Lyon; Paul Harmatz; Matthew Mealiffe; Sean Mooney; Tal Ronnen Oron; April Ryles; Karl A Zawadzki; Nicole Miller
Journal:  Hum Mutat       Date:  2014-09-17       Impact factor: 4.878

Review 6.  Pharmaceutical Chaperones and Proteostasis Regulators in the Therapy of Lysosomal Storage Disorders: Current Perspective and Future Promises.

Authors:  Fedah E Mohamed; Lihadh Al-Gazali; Fatma Al-Jasmi; Bassam R Ali
Journal:  Front Pharmacol       Date:  2017-07-07       Impact factor: 5.810

Review 7.  Mucopolysaccharidosis type VI (MPS VI) and molecular analysis: Review and classification of published variants in the ARSB gene.

Authors:  Rosella Tomanin; Litsa Karageorgos; Alessandra Zanetti; Moeenaldeen Al-Sayed; Mitch Bailey; Nicole Miller; Hitoshi Sakuraba; John J Hopwood
Journal:  Hum Mutat       Date:  2018-09-17       Impact factor: 4.878

Review 8.  Biochemical and molecular analysis in mucopolysaccharidoses: what a paediatrician must know.

Authors:  Mirella Filocamo; Rosella Tomanin; Francesca Bertola; Amelia Morrone
Journal:  Ital J Pediatr       Date:  2018-11-16       Impact factor: 2.638

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.